• 1
    Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 3547.
  • 2
    McOmish F, Yap PL, Dow BC, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994; 32: 88492.
  • 3
    Esmat G, El Raziky M, El Kassas M, Hassany M, Gamil ME. The future for the treatment of genotype 4 chronic hepatitis C. Liver Int 2012; 32(Suppl. 1): 14650.
  • 4
    Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 22837.
  • 5
    Kamal SM, El Tawil AA, Nakano T, et al. Peginterferon alpha-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54: 85866.
  • 6
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 7
    Hadziyannis SJ, Sette H Jr., Morgan TR, et al. PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 34655.
  • 8
    Hasan F, Asker H, Al-Khaldi J, et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004; 99: 17337.
  • 9
    Fan X, Mao Q, Zhou D, et al. High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy. Hepatology 2009; 50: 176572.
  • 10
    Al-Qahtani AA, Kessie G, Dela Cruz D, Al-Faleh FZ, Al-Ahdal MN. Quasispecies of genotype 4 of hepatitis C virus genomes in Saudi patients managed with interferon alfa and ribavirin therapy. Ann Saudi Med 2010; 30: 10914.
  • 11
    Asselah T, De Muynck S, Broët P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012; 56: 52732.
  • 12
    Lagging M, Askarieh G, Negro F, et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS ONE 2011; 6: e17232.
  • 13
    El-ShamyA , Shoji I, El-Akel al. Sequence heterogeneity in NS5A of hepatitis c virus genotype 4 predicts clinical outcome of pegylated-interferon/ribavirin therapy. J Clin Microbiol, 2012; 50: 388692.
  • 14
    Papastergiou V, Dimitroulopoulos D, Skorda L, et al. Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter? J Med Virol 2012; 84: 121723.
  • 15
    Wirth S, Ribes-Koninckx C, Calzado MA, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010; 52: 5017.
  • 16
    Dimitroulopoulos D, Elefsiniotis I, Pavlidis C., et al. European vs. Egyptian HCV-4 patients with elevated baseline HCV RNA, treated with PEG-IFN-α2a and ribavirin: the role of rapid and early virologic response.. Hepat Mon 2010; 10: 1938.
  • 17
    Roulot D, Bourcier V, Grando V, et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007; 2007: 4607.
  • 18
    Moucari R, Ripault MP, Martinot-Peignoux M, et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009; 58: 16629.
  • 19
    Gad RR, Males S, El Makhzangy H, et al. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. Liver Int 2008; 28: 11129.
  • 20
    De Careaga BO. Predictive factors for response to treatment of chronic hepatitis C. Ann Hepatol 2006; 5(suppl. 1): S248.
  • 21
    Esmat G, El Akel W, Metwally M., et al. Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss. Indian J Gastroenterol 2009; 28: 458.
  • 22
    El-Shazly Y, Rafeek M, Al-Swaff R. Effect of well controlled diabetes mellitus on sustained virologic response in chronic HCV genotype 4 infected patients. Journal of Diabetology 2012; 2: 3.
  • 23
    Khattab M, Eslam M, Sharwae MA, et al. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 2010; 105: 19707.
  • 24
    Khattab M, Emad M, Abdelaleem A, et al. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int 2010; 30: 44754.
  • 25
    Unicef country statistics. Available at
  • 26
    El-Zayadi A, Hepatitis B. Virus infection the Egyptian situation. Arab J Gastroenterol 2007; 8: 948.
  • 27
    Sterling RK, Sulkowski MS. Hepatitis C virus in the the setting of HIV OR Hepatitis B virus coinfection. Seminars Liver Dis 2004; 4: 112.
  • 28
    Sakuma I, Enomoto N, Kurosaki M, et al. Differntial effect of interferon on hepatitis C virus Ib quasispecies in the nonstructural protein 5A gene. J Infect Dis 1999; 180: 10019.
  • 29
    Brechot C, Thiers V, Kremsdorf D, et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely “occult”? Hepatol 2001; 34: 194203.
  • 30
    Elsharkawy A, Esmat G, Elraziky M, et al. HCV/Schistosomiasis coinfection: impact on fibrosis and response to pegylated interferon and Ribavirin therapy in chronic HCV patients. J Hepatol 2012; 56(Suppl): S61.
  • 31
    Esmat G, El-Bendary M, Zakarya S, Ela MA, Zalata K. Role of Helicobacter pylori in patients with HCV-related chronic hepatitis and cirrhosis with or without hepatocellular carcinoma: possible association with disease progression. J Viral Hepat 2012; 19: 4739.
  • 32
    Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012; 32(Suppl. 1): 88102.
  • 33
    Manns MP, Foster GR, Rockstroh JK, et al. The way forward in HCV treatment-finding the right path. Nat Rev Drug Discov 2007; 6: 9911000.
  • 34
    Benhamou Y, Moussalli J, Ratziu V, et al. Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon alfa-2a and ribavirin in treatment-naïve genotype 4 HCV patients. J Hepatol 2009; 50(Suppl): S6.
  • 35
    Seiwert SD, Andrews SW, Jiang Y, et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother 2008; 52: 443241.
  • 36
    Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study. J Hepatol 2012; 56: 124753.
  • 37
    McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 10619.
  • 38
    Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 23164.
  • 39
    McCaughan GW, Omata M, Amarapurkar D, et al. APASL Consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. APASL Hepatitis C Working Party, et al.. J Gastroenterol Hepatol 2007;22 L61533.
  • 40
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 95865.
  • 41
    Khattab MA, Ferenci P, Hadziyannis SJ, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011; 54: 125062.
  • 42
    Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 42533.
  • 43
    Kamal SM, El Kamary SS, Shardell MD, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 2007; 46: 173240.
  • 44
    Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1and 4 patients with rapid virological response. Gastroenterology 2008; 135: 4518.
  • 45
    Estrabaud E, Vidaud M, Marcellin P, Asselah T. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol 2012; 57: 111025.